An International, Non-Comparative, Open-Label Study of PS-341 [bortezomib] Administered to Patients With Multiple Myeloma Who Experienced Relapsed or Progressive Disease After Receiving at Least Four Previous Treatment Regimens or Experienced Progressive Disease After Receiving Dexamethasone in FHCRC [Fred Hutchinson Cancer Research Center] Protocol 1746.00
Latest Information Update: 27 Sep 2005
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 27 Sep 2005 New trial record.